Takeover row fails to derail Sanofi-Aventis and Genzyme business
This article was originally published in Scrip
Executive Summary
Both Sanofi-Aventis and Genzyme have managed to retain a steady business course and avoid any potential distraction associated with their protracted takeover battle. Speaking at the JP Morgan Healthcare conference in San Francisco, both companies' CEOs spent their time highlighting progress in their core businesses, referring to the discussions between the two companies only in passing.